The company said results from a study of European men are consistent with prior studies of men with early prostate cancer that were conducted in the United States.
Myriad Genetics, Inc., has announced that it will present results from a study of its Prolaris prostate cancer test at the 30th Annual Congress of the European Association of Urology, which starts today in Madrid, Spain. The announcement came jointly from Myriad offices in Salt Lake City, Utah, and Zurich, Switzerland.
Results of the study show that 42% of men from 5 European countries had a risk profile either lower or higher than would be expected using clinical pathology. The company’s statement said the finding is consistent with the previously published US Prostate Biopsy Research study, which found the 51% of US patients had risk profile that differed from clinical pathology.
The EMPATHY-P clinical study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in men with a new diagnosis. Patients came from Italy, Germany, Switzerland, Spain, and the United Kingdom. Samples were evaluated using standard methods, including risk stratification according to American Urological Association standards; then they were compared with Prolaris results.
"EMPATHY-P showed that Prolaris provides valuable clinical information that can help physicians improve healthcare and outcomes for their patients with early prostate cancer," said Colin Hayward, MD, Myriad's European medical director. "There is no one-size-fits-all treatment approach in prostate cancer. Prolaris provides objective genetic information to help clinicians tailor treatment plans based on patients' individual risk profiles."
Prolaris is a 46-gene RNA-expression tests that measures tumor cell growth to determine the risk of disease progression in cancer patients.